This is a preview of subscription content, access via your institution.
References
Argoff CE, Katz N, Backonja M (2004) Treatment of postherpetic neuralgia: a review of therapeutic options. J Pain Symptom Manage 28:396–411
Arvin AM (2013) Varicella-zoster virus. Fileds virology, 6th edn. Wolters Kluwer Health, Philadelphia
Asano Y, Itakura N, Hiroishi Y, Hirose S, Ozaki T, Kuno K, Nagai T, Yazaki T, Yamanishi K, Takahashi M (1985) Viral replication and immunologic responses in children naturally infected with varicella-zoster virus and in varicella vaccine recipients. J Infect Dis 152:863–868
Asano Y, Suga S, Yoshikawa T, Kobayashi I, Yazaki T, Shibata M, Tsuzuki K, Ito S (1994) Experience and reason: twenty-year follow-up of protective immunity of the Oka strain live varicella vaccine. Pediatrics 94:524–526
Cunningham AL, Lal H, Kovac M, Chlibek R, Hwang SJ, Diez-Domingo J, Godeaux O, Levin MJ, McElhaney JE, Puig-Barbera J, Van den Abeele C, Vesikari T, Watanabe D, Zahaf T, Ahonen A, Athan E, Barba-Gomez JF, Campora L, de Looze F, Downey HJ, Ghesquiere W, Gorfinkel I, Korhonen T, Leung E, McNeil SA, Oostvogels L, Rombo L, Smetana J, Weckx L, Yeo W, Heineman TC, Group ZOES (2016) Efficacy of the Herpes Zoster subunit vaccine in adults 70 years of age or older. N Engl J Med 375:1019–1032
Deng X, Xu W, Yan R, Chen H, Shen W, Zhang M, Wu T, Xu B, He H, Ma Y (2016) Immunogenicity and safety of different schedules of 2-dose varicella vaccination in China. Hum Vaccin Immunother 12:3113–3117
Forbes HJ, Bhaskaran K, Thomas SL, Smeeth L, Clayton T, Mansfield K, Minassian C, Langan SM (2016) Quantification of risk factors for postherpetic neuralgia in herpes zoster patients: a cohort study. Neurology 87:94–102
Galea SA, Sweet A, Beninger P, Steinberg SP, Larussa PS, Gershon AA, Sharrar RG (2008) The safety profile of varicella vaccine: a 10-year review. J Infect Dis 197(Suppl 2):S165–169
Gershon AA, Breuer J, Cohen JI, Cohrs RJ, Gershon MD, Gilden D, Grose C, Hambleton S, Kennedy PG, Oxman MN, Seward JF, Yamanishi K (2015) Varicella zoster virus infection. Nat Rev Dis Primers 1:15016
Jeon YH (2015) Herpes zoster and postherpetic neuralgia: practical consideration for prevention and treatment. Korean J Pain 28:177–184
Jiang HF, Wang W, Jiang X, Zeng WB, Shen ZZ, Song YG, Yang H, Liu XJ, Dong X, Zhou J, Sun JY, Yu FL, Guo L, Cheng T, Rayner S, Zhao F, Zhu H, Luo MH (2017) ORF7 of varicella-zoster virus is required for viral cytoplasmic envelopment in differentiated neuronal cells. J Virol 91:e00127
Johnson BH, Palmer L, Gatwood J, Lenhart G, Kawai K, Acosta CJ (2015a) Annual incidence rates of herpes zoster among an immunocompetent population in the United States. BMC Infect Dis 15:502
Johnson RW, Alvarez-Pasquin MJ, Bijl M, Franco E, Gaillat J, Clara JG, Labetoulle M, Michel JP, Naldi L, Sanmarti LS, Weinke T (2015b) Herpes zoster epidemiology, management, and disease and economic burden in Europe: a multidisciplinary perspective. Ther Adv Vaccines 3:109–120
Lal H, Cunningham AL, Godeaux O, Chlibek R, Diez-Domingo J, Hwang SJ, Levin MJ, McElhaney JE, Poder A, Puig-Barbera J, Vesikari T, Watanabe D, Weckx L, Zahaf T, Heineman TC, Group ZOES (2015) Efficacy of an adjuvanted herpes zoster subunit vaccine in older adults. N Engl J Med 372:2087–2096
Lo L, Anderson DJ (2011) A Cre-dependent, anterograde transsynaptic viral tracer for mapping output pathways of genetically marked neurons. Neuron 72:938–950
Miranda-Saksena M, Boadle RA, Diefenbach RJ, Cunningham AL (2015) Dual role of herpes simplex virus 1 pUS9 in virus anterograde axonal transport and final assembly in growth cones in distal axons. J Virol 90:2653–2663
Oxman MN, Levin MJ, Johnson GR, Schmader KE, Straus SE, Gelb LD, Arbeit RD, Simberkoff MS, Gershon AA, Davis LE, Weinberg A, Boardman KD, Williams HM, Zhang JH, Peduzzi PN, Beisel CE, Morrison VA, Guatelli JC, Brooks PA, Kauffman CA, Pachucki CT, Neuzil KM, Betts RF, Wright PF, Griffin MR, Brunell P, Soto NE, Marques AR, Keay SK, Goodman RP, Cotton DJ, Gnann JW Jr, Loutit J, Holodniy M, Keitel WA, Crawford GE, Yeh SS, Lobo Z, Toney JF, Greenberg RN, Keller PM, Harbecke R, Hayward AR, Irwin MR, Kyriakides TC, Chan CY, Chan IS, Wang WW, Annunziato PW, Silber JL, Shingles Prevention Study Group (2005) A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. N Engl J Med 352:2271–2284
Pan X, Shu M, Ma R, Fang T, Dong H, Sun Y, Xu G (2018) Varicella breakthrough infection and effectiveness of 2-dose varicella vaccine in China. Vaccine 36:5665–5670
Pastuszak AL, Levy M, Schick B, Zuber C, Feldkamp M, Gladstone J, Bar-Levy F, Jackson E, Donnenfeld A, Meschino W et al (1994) Outcome after maternal varicella infection in the first 20 weeks of pregnancy. N Engl J Med 330:901–905
Schmader KE, Levin MJ, Gnann JW Jr, McNeil SA, Vesikari T, Betts RF, Keay S, Stek JE, Bundick ND, Su SC, Zhao Y, Li X, Chan IS, Annunziato PW, Parrino J (2012) Efficacy, safety, and tolerability of herpes zoster vaccine in persons aged 50–59 years. Clin Infect Dis 54:922–928
Schuster V, Otto W, Maurer L, Tcherepnine P, Pfletschinger U, Kindler K, Soemantri P, Walther U, Macholdt U, Douha M, Pierson P, Willems P (2008) Immunogenicity and safety assessments after one and two doses of a refrigerator-stable tetravalent measles-mumps-rubella-varicella vaccine in healthy children during the second year of life. Pediatr Infect Dis J 27:724–730
Selariu A, Cheng T, Tang Q, Silver B, Yang L, Liu C, Ye X, Markus A, Goldstein RS, Cruz-Cosme RS, Lin Y, Wen L, Qian H, Han J, Dulal K, Huang Y, Li Y, Xia N, Zhu H (2012) ORF7 of varicella-zoster virus is a neurotropic factor. J Virol 86:8614–8624
Takahashi M, Otsuka T, Okuno Y, Asano Y, Yazaki T (1974) Live vaccine used to prevent the spread of varicella in children in hospital. Lancet 2:1288–1290
Weibel RE, Neff BJ, Kuter BJ, Guess HA, Rothenberger CA, Fitzgerald AJ, Connor KA, McLean AA, Hilleman MR, Buynak EB et al (1984) Live attenuated varicella virus vaccine. Efficacy trial in healthy children. N Engl J Med 310:1409–1415
Weinmann S, Chun C, Schmid DS, Roberts M, Vandermeer M, Riedlinger K, Bialek SR, Marin M (2013) Incidence and clinical characteristics of herpes zoster among children in the varicella vaccine era, 2005–2009. J Infect Dis 208:1859–1868
Whitley RJ, Volpi A, McKendrick M, Wijck A, Oaklander AL (2010) Management of herpes zoster and post-herpetic neuralgia now and in the future. J Clin Virol 48(Suppl 1):S20–28
Woodward M, Marko A, Galea S, Eagel B, Straus W (2019) Varicella virus vaccine live: a 22-year review of postmarketing safety data. Open forum infectious diseases. Oxford University Press, Oxford
Wu QS, Wang X, Liu JY, Chen YF, Zhou Q, Wang Y, Sha JD, Xuan ZL, Zhang LW, Yan L, Hu Y (2019) Varicella outbreak trends in school settings during the voluntary single-dose vaccine era from 2006 to 2017 in Shanghai, China. Int J Infect Dis 89:72–78
Yoshikawa T, Ando Y, Nakagawa T, Gomi Y (2016) Safety profile of the varicella vaccine (Oka vaccine strain) based on reported cases from 2005 to 2015 in Japan. Vaccine 34:4943–4947
Zeng WB, Jiang HF, Gang YD, Song YG, Shen ZZ, Yang H, Dong X, Tian YL, Ni RJ, Liu Y, Tang N, Li X, Jiang X, Gao D, Androulakis M, He XB, Xia HM, Ming YZ, Lu Y, Zhou JN, Zhang C, Xia XS, Shu Y, Zeng SQ, Xu F, Zhao F, Luo MH (2017) Anterograde monosynaptic transneuronal tracers derived from herpes simplex virus 1 strain H129. Mol Neurodegener 12:38
Author information
Authors and Affiliations
Corresponding authors
Ethics declarations
Conflict of interest
The authors declare that they have no conflict of interest.
Animal and Human Rights Statement
This article does not contain any studies with human or animal subjects performed by any of the authors.
Rights and permissions
About this article
Cite this article
Zeng, WB., Zhang, F., Cheng, S. et al. Concerns on Vaccine against Varicella Caused by Varicella-Zoster Virus Infection. Virol. Sin. 36, 159–162 (2021). https://doi.org/10.1007/s12250-020-00231-4
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12250-020-00231-4